Which medicine works best for fatty liver disease?

Original Title

Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

Doctors tested different medicines to see which one works best for fatty liver disease. They looked at how well each drug reduced fat and stiffness in the liver.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

FGF-21 analogues were most effective for liver stiffness, not GLP-1 drugs

Most attention has been on GLP-1 drugs like semaglutide for liver disease, but this study suggests FGF-21 may be superior for fibrosis—a key surprise.

Practical Takeaways

People with MASLD may benefit from newer GLP-1-based polyagonists for reducing liver fat, especially if fat accumulation is the main concern.

low confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

49%
Moderate QualityOverall Score

Publication

Journal

Metabolism: clinical and experimental

Year

2024

Authors

Rutao Lin, Qin-mei Sun, Xin Xin, Cheng Han Ng, Luca Valenti, Yi-Yang Hu, Ming-Hua Zheng, Qin Feng

45 citations
Analysis v1